CARLSBAD, Calif.--(BUSINESS WIRE)--GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the first quarter ended March 31, 2016.
Revenue for the first quarter of 2016 was $11.1 million, an increase of 9% over the prior year period.
Gross profit for the first quarter was $6.7 million, or 60% of revenue, compared with $6.1 million, or 61% of revenue in the same period of 2015.
Revenue for the first quarter of 2016 was $11.1 million, an increase of 9% over the prior year period.
Gross profit for the first quarter was $6.7 million, or 60% of revenue, compared with $6.1 million, or 61% of revenue in the same period of 2015.
